Clinical Trials Logo

Clinical Trial Summary

This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01925209
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 26, 2013
Completion date January 6, 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05046821 - Sporadic Inclusion Body Myositis Natural History Study
Completed NCT02573467 - An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Phase 3
Not yet recruiting NCT02735447 - Evidence Generation for Improving Life of People With sIBM: The ENGAGE Study N/A
Completed NCT02317094 - Blood-flow Restricted Exercise in Inclusion Body Myositis N/A
Completed NCT01519349 - Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis Phase 1
Withdrawn NCT03710941 - Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis Phase 2
Completed NCT01423110 - Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Phase 2
Completed NCT04421677 - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Phase 1